FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307049726> ?p ?o ?g. }

• W4307049726 endingPage "8" @default.
• W4307049726 startingPage "1" @default.
• W4307049726 abstract "OBJECTIVE Neurofibromatosis type 2 (NF2) is a rare autosomal dominant syndrome associated primarily with bilateral vestibular schwannomas (VSs). Conventional surgical or radiosurgical treatments for VS in NF2 usually result in high risks of hearing loss and facial nerve impairment, while there is no validated medical option to date. This single-institution phase II study evaluated the efficacy and safety of icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with NF2 and progressive VS. METHODS Icotinib was administered daily at 375 mg orally in a continuous 28-day course for up to 12 courses. The primary endpoint of the study was radiographic response assessed by brain MRI using 3D volumetric tumor analysis and defined as a ≥ 20% decrease in VS volume. Hearing function was evaluated as a secondary endpoint, with response defined as a statistically significant increase in word recognition scores. RESULTS Ten eligible patients with a mean age of 23.8 years were enrolled. One patient (10%) with bilateral tumors experienced an objective radiographic response (−23.58% and −22.01%). Three (43%) of 7 patients met the hearing response criteria. At 12 months, the estimated progression-free survival was 82.0% (95% CI 42.3%–95.5%) for volumetric progression and 69.2% (95% CI 37.3%−87.2%) for hearing progression. Common mild to moderate adverse events included rash (90%), diarrhea (50%), myalgia (20%), and nausea/gastrointestinal pain (20%). CONCLUSIONS Icotinib carries minor toxicity and is associated with radiographic and hearing responses in patients with NF2 and progressive VS." @default.
• W4307049726 created "2022-10-23" @default.
• W4307049726 creator A5017947172 @default.
• W4307049726 creator A5019691586 @default.
• W4307049726 creator A5043828090 @default.
• W4307049726 creator A5054477458 @default.
• W4307049726 creator A5055218149 @default.
• W4307049726 creator A5056168495 @default.
• W4307049726 creator A5060613485 @default.
• W4307049726 creator A5067782718 @default.
• W4307049726 creator A5068680537 @default.
• W4307049726 creator A5071458554 @default.
• W4307049726 date "2022-10-01" @default.
• W4307049726 modified "2023-09-23" @default.
• W4307049726 title "Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma" @default.
• W4307049726 cites W1607495703 @default.
• W4307049726 cites W1967535091 @default.
• W4307049726 cites W1970705227 @default.
• W4307049726 cites W1973106770 @default.
• W4307049726 cites W1974290681 @default.
• W4307049726 cites W1990309105 @default.
• W4307049726 cites W2010793999 @default.
• W4307049726 cites W2023011946 @default.
• W4307049726 cites W2026383115 @default.
• W4307049726 cites W2031436472 @default.
• W4307049726 cites W2056950677 @default.
• W4307049726 cites W2064339362 @default.
• W4307049726 cites W2078364195 @default.
• W4307049726 cites W2090167417 @default.
• W4307049726 cites W2099180737 @default.
• W4307049726 cites W2101219402 @default.
• W4307049726 cites W2105968454 @default.
• W4307049726 cites W2114550587 @default.
• W4307049726 cites W2122724278 @default.
• W4307049726 cites W2130676729 @default.
• W4307049726 cites W2168778512 @default.
• W4307049726 cites W2170249858 @default.
• W4307049726 cites W2172251568 @default.
• W4307049726 cites W2302223557 @default.
• W4307049726 cites W2322464103 @default.
• W4307049726 cites W2323645639 @default.
• W4307049726 cites W2511581089 @default.
• W4307049726 cites W2543372228 @default.
• W4307049726 cites W2604815509 @default.
• W4307049726 cites W2739010860 @default.
• W4307049726 cites W2747505649 @default.
• W4307049726 cites W2791604424 @default.
• W4307049726 cites W2898673849 @default.
• W4307049726 cites W2948987558 @default.
• W4307049726 cites W2981209726 @default.
• W4307049726 cites W2999188432 @default.
• W4307049726 cites W4293310085 @default.
• W4307049726 doi "https://doi.org/10.3171/2022.9.jns22699" @default.
• W4307049726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36272122" @default.
• W4307049726 hasPublicationYear "2022" @default.
• W4307049726 type Work @default.
• W4307049726 citedByCount "2" @default.
• W4307049726 countsByYear W43070497262023 @default.
• W4307049726 crossrefType "journal-article" @default.
• W4307049726 hasAuthorship W4307049726A5017947172 @default.
• W4307049726 hasAuthorship W4307049726A5019691586 @default.
• W4307049726 hasAuthorship W4307049726A5043828090 @default.
• W4307049726 hasAuthorship W4307049726A5054477458 @default.
• W4307049726 hasAuthorship W4307049726A5055218149 @default.
• W4307049726 hasAuthorship W4307049726A5056168495 @default.
• W4307049726 hasAuthorship W4307049726A5060613485 @default.
• W4307049726 hasAuthorship W4307049726A5067782718 @default.
• W4307049726 hasAuthorship W4307049726A5068680537 @default.
• W4307049726 hasAuthorship W4307049726A5071458554 @default.
• W4307049726 hasConcept C126322002 @default.
• W4307049726 hasConcept C141071460 @default.
• W4307049726 hasConcept C197934379 @default.
• W4307049726 hasConcept C203092338 @default.
• W4307049726 hasConcept C2778570526 @default.
• W4307049726 hasConcept C2778679214 @default.
• W4307049726 hasConcept C2780493683 @default.
• W4307049726 hasConcept C2780580376 @default.
• W4307049726 hasConcept C2781447767 @default.
• W4307049726 hasConcept C535046627 @default.
• W4307049726 hasConcept C548259974 @default.
• W4307049726 hasConcept C71924100 @default.
• W4307049726 hasConceptScore W4307049726C126322002 @default.
• W4307049726 hasConceptScore W4307049726C141071460 @default.
• W4307049726 hasConceptScore W4307049726C197934379 @default.
• W4307049726 hasConceptScore W4307049726C203092338 @default.
• W4307049726 hasConceptScore W4307049726C2778570526 @default.
• W4307049726 hasConceptScore W4307049726C2778679214 @default.
• W4307049726 hasConceptScore W4307049726C2780493683 @default.
• W4307049726 hasConceptScore W4307049726C2780580376 @default.
• W4307049726 hasConceptScore W4307049726C2781447767 @default.
• W4307049726 hasConceptScore W4307049726C535046627 @default.
• W4307049726 hasConceptScore W4307049726C548259974 @default.
• W4307049726 hasConceptScore W4307049726C71924100 @default.
• W4307049726 hasLocation W43070497261 @default.
• W4307049726 hasLocation W43070497262 @default.
• W4307049726 hasOpenAccess W4307049726 @default.
• W4307049726 hasPrimaryLocation W43070497261 @default.
• W4307049726 hasRelatedWork W2343034073 @default.

• next